WATCH NOW: 'Next-generation communication beyond Voice, Video, Data' webinar; powered by Intel and Jio Talks infinity.
you are here: HomeNewsIndia
Last Updated : Sep 22, 2020 12:23 PM IST | Source: Moneycontrol.com

COVID-19 vaccines, if developed in India, need antibody response in at least 50% cases for approval

COVID-19 vaccines developed outside India will get authorisation on the basis of clinical trial data.

According to the draft guidelines for the development of COVID-19 vaccines, a vaccine developed in India should prove that at least 50 percent of those administered with the vaccine are protected from the virus to get an approval.

For vaccines that are being developed outside India, the authorisation will be provided on the basis of clinical trial data once they pass evaluation for the overall safety and effectiveness of the vaccine.


"However, an additional clinical trial may be required in the local population to confirm the safety and effectiveness in Indian population. The extent of local clinical trial requirements will be decided on a case by case basis," the draft guidelines, released by Central Drugs Standard Control Organisation (CDSCO) on September 21, read.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more

Track this LIVE blog for all the latest updates on coronavirus pandemic

India’s vaccine guidelines are in line with recommendations made by the US Food and Drug Administration (FDA) and World Health Organisation (WHO).

The 40-page document titled 'Draft Regulatory Guidelines For Development of Vaccines With Special Consideration For COVID-19 Vaccine' has several safety protocols that companies have to follow while developing and manufacturing the vaccine.

Considering the urgent need of a safe and effective vaccine to contain the spread of coronavirus pandemic, Drugs Controller General of India has allowed clinical development programs of COVID-19 vaccine to proceed using adaptive and seamless approach.

While a seamless design combines two separate trials (individual Phase 2 and Phase 3 trials) into one trial, an adaptive seamless design makes use of information (data) from patients enrolled before and after adaptation (pulls together data collected in both the Phase 2 and Phase 3 trials) in the final analysis.

Read: More than 150 nations join WHO-led global plan for COVID-19 vaccines

"However, regardless of whether clinical development of COVID-19 vaccine proceeds with separate studies or via a seamless approach, adequate data, including data to inform the potential risk of vaccine-associated Enhanced Respiratory Disease (ERD), will be needed," as per the draft framework.

Noting that the understanding of SARS-CoV-2 immunology is currently evolving, the CDSCO said that the predictive value of the immune response for short-term and/or longer-term protection from SARS-CoV-2

infection and/or disease may be investigated.

Also read: Phase 3 human clinical trial of Oxford vaccine begins in Pune

"Once the vaccine is approved for marketing, the direct evidence of vaccine efficacy in protection from SARS-CoV-2 infection must be accessed through appropriate study in Post Marketing Scenario," the guidelines said, adding that clinical development programs for COVID-19 vaccines might be expedited for more rapid progression.

CDSCO has sought comments on the draft framework till October 12.

Click here for Moneycontrol's full coverage of the COVID-19 outbreak
First Published on Sep 22, 2020 09:30 am